MedTrace Logo

Dexmedetomidine on Postoperative Cognitive Dysfunction and Serum Tau-217 Protein.

NCT06366412 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2024-04-15

No results posted yet for this study

Summary

To assess the effect of Dexmedetomidine on serum Tau-217 protein and its relation to the incidence and severity of postoperative cognitive dysfunction in elderly patients undergoing major surgery under general anesthesia.

Conditions

Interventions

DRUG

Dexmedetomidine Hydrochloride

dexmedetomidine effect in preventing postoperative cognitive dysfunction on elderly patients undergoing major surgery guided with serum Tau-217 protein.

OTHER

normal saline

normal saline will be administrated in placebo group

Sponsors & Collaborators

  • Minia University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-30
Primary Completion
2025-03-31
Completion
2026-03-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06366412 on ClinicalTrials.gov